Search results
1 sty 2022 · Metronomic chemotherapy is a treatment option for metastatic breast cancer (MBC) patients who require prolonged disease control without cumulative toxicity. Data available on the efficacy and tolerability of prolonged usage of metronomic therapy are limited.
Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study. Breast Cancer Res Treat. 2016;160(3):501-509. doi:10.1007/s10549-016-4009-3 PubMed Google Scholar Crossref
1 wrz 2023 · The METEORA-II trial compared a metronomic all-oral treatment with intravenous (IV) chemotherapy. Objective: To compare the efficacy of the oral vinorelbine plus cyclophosphamide plus capecitabine (VEX) regimen vs weekly IV paclitaxel among patients with ER+/ERBB2- MBC who are candidates for chemotherapy.
Metronomic chemotherapy is a treatment option for metastatic breast cancer (MBC) patients who require prolonged disease control without cumulative toxicity. Data available on the efficacy and tolerability of prolonged usage of metronomic therapy are limited.
Oral chemotherapy is a cancer-fighting drug given by mouth in tablet, capsule, or liquid form, and taken at home. Learn what oral chemotherapy is, and how it has the same benefits and risks as chemotherapy given by infusion. What information should you gather before you begin oral chemotherapy?
Methods: This phase II study assessed the safety and efficacy of metronomic oral chemotherapy with vinorelbine 40 mg orally 3 times a week, cyclophosphamide 50 mg daily, and capecitabine 500 mg 3 times a day (VEX regimen) in untreated metastatic triple-negative breast cancer patients.
• Your treatment team may prescribe Xeloda (capecitabine) to control and reduce cancer if you have: ‒ A personal history of metastatic breast cancer ‒ A personal history of early stage HER2- breast cancer with residual disease, or cancer cells that
